MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of
RCC representing the most prevalent RCC in the pediatric population (up to 40%) and …

The advent of precision medicine has changed the landscape of oncologic biomarkers, drug
discovery, drug development, and, more importantly, outcomes for patients with cancer …

Introduction Cellular senescence (CS) plays a critical role in cancer development, including
clear cell renal cell carcinoma (ccRCC). Traditional RNA sequencing cannot detect precise …

Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene
rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor …

Simple Summary Tyrosine kinase inhibitors and immune checkpoint inhibitors have
substantially prolonged survival in patients affected by advanced renal cell carcinoma …

Background Recent studies have demonstrated that earlier time-of-day infusion of immune
checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and …

Approximately 79,000 cases of renal cell carcinoma (RCC) will be diagnosed in the United
States in 2022, with 13,920 deaths attributed to RCC. 1 Localized RCC has numerous …

Simple Summary Nowadays, most metastatic renal cell carcinoma (mRCC) patients are
candidates for immunotherapy. Risk stratification is based on the IMDC model that was …

The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in
recent years have fuelled the ongoing development of this class of drugs. These novel …

The treatment of urological cancers has been significantly improved in recent years.
However, for the advanced stages of these cancers and/or for those developing resistance …